Patents by Inventor Katrina A. Bollinger

Katrina A. Bollinger has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • 7,8-DIHYDRO-5H-1,6-NAPHTHYRIDINE DERIVATIVES AS POSITIVE ALLOSTERIC MODULATORS OF THE MUSCARINIC ACETYLCHOLINE RECEPTOR M4 FOR TREATING NEUROLOGICAL AND PSYCHIATRIC DISORDERS
    Publication number: 20250002507
    Abstract: The present invention relates to 6-([1,2,4]triazolo[4,3-b]pyridazin-6-yl)-7,8-dihydro-5H-1,6-naphthyridine derivatives, 6-(imidazo[1,2-b]pyridazin-6-yl)-7,8-dihydro-5H-1,6-naphthyridine derivatives or 6-(imidazo[1,5-b]pyridazin-6-yl)-7,8-dihydro-5H-1,6-naphthyridine derivatives of formula (I) The present compounds are positive allosteric modulators of the muscarinic acetylcholine receptor M4 (mAChR M4) for use in treating neurological and psychiatric disorders associated with muscarinic acetylcholine receptor dysfunction. An exemplary compound is e.g. compound 1 Data on the activity of exemplary compounds in an mAChR M4 cell-based assay is provided.
    Type: Application
    Filed: October 14, 2022
    Publication date: January 2, 2025
    Inventors: Craig W. Lindsley, P. Jeffrey Conn, Darren W. Engers, Alison R. Gregro, Katrina A. Bollinger, Charlotte Park, Kayla J. Temple, Logan A. Baker, Madeline F. Long, Anna E. Ringuette, Julie L. Engers
  • ANTAGONISTS OF THE MUSCARINIC ACETYLCHOLINE RECEPTOR M4
    Publication number: 20230150986
    Abstract: Disclosed herein are 2,3,5-trifluorophenyl-pyridazine substituted hexahydro-1H-cyclopenta[c]pyrrole compounds, useful as antagonists of the muscarinic acetylcholine receptor M4 (mAChR M4) Also disclosed herein are methods of making the compounds, pharmaceutical compositions comprising the compounds, and methods of treating disorders using the compounds and compositions.
    Type: Application
    Filed: December 10, 2020
    Publication date: May 18, 2023
    Inventors: Craig W. Lindsley, P. Jeffrey Conn, Aaron M. Bender, Katrina A. Bollinger, Trever R. Carter, Jerri M. Rook, Jonathan W. Dickerson, Julie L. Engers, Kayla J. Temple, Changho Han, Matthew Spock, Logan A. Baker, Thomas M. Bridges
  • Positive allosteric modulators of the muscarinic acetylcholine receptor M
    Patent number: 11111251
    Abstract: Described are positive allosteric modulators of muscarinic acetylcholine receptor M1 (mAChR M1), pharmaceutical compositions including the compounds, and methods of using the compounds and compositions for treating neurological disorders, psychiatric disorders, or a combination thereof.
    Type: Grant
    Filed: February 16, 2017
    Date of Patent: September 7, 2021
    Assignee: Vanderbilt University
    Inventors: Craig W. Lindsley, P. Jeffrey Conn, Darren W. Engers, Katrina A. Bollinger, Julie L. Engers
  • POSITIVE ALLOSTERIC MODULATORS OF THE MUSCARINIC ACETYLCHOLINE RECEPTOR M1
    Publication number: 20210230180
    Abstract: Described are positive allosteric modulators of muscarinic acetylcholine receptor M1 (mAChR M1), pharmaceutical compositions including the compounds, and methods of using the compounds and compositions for treating neurological disorders, psychiatric disorders, or a combination thereof.
    Type: Application
    Filed: February 16, 2017
    Publication date: July 29, 2021
    Inventors: Craig W. Lindsley, P. Jeffrey Conn, Darren W. Engers, Katrina A. Bollinger, Julie L. Engers
  • POSITIVE ALLOSTERIC MODULATORS OF THE MUSCARINIC ACETYLCHOLINE RECEPTOR M1
    Publication number: 20210130348
    Abstract: Described are positive allosteric modulators of muscarinic acetylcholine receptor M1 (mAChR M1), pharmaceutical compositions including the compounds, and methods of using the compounds and compositions for treating neurological disorders, psychiatric disorders, or a combination thereof.
    Type: Application
    Filed: December 15, 2020
    Publication date: May 6, 2021
    Inventors: Craig W. Lindsley, P. Jeffrey Conn, Katrina A. Bollinger, Darren W. Engers, Anna L. Blobaum, Julie L. Engers, Jerri M. Rook
  • Positive allosteric modulators of the muscarinic acetylcholine receptor M4
    Patent number: 10961253
    Abstract: Disclosed herein are pyrido[3?,2?:4,5]thieno[3,2-d]pyrimidine and pyrimido[4?,5?:4,5]thieno[2,3-c]pyridazine compounds, which may be useful as positive allostenc modulators of the muscarinic acetylcholine receptor M4 (mAChR M4). Also disclosed herein are methods of making the compounds, pharmaceutical compositions comprising the compounds, and methods of treating neurological and psychiatric disorders associated with muscarinic acetylcholine receptor dysfunction using the compounds and compositions.
    Type: Grant
    Filed: November 7, 2017
    Date of Patent: March 30, 2021
    Assignee: Vanderbilt University
    Inventors: Craig W. Lindsley, Darren W. Engers, P. Jeffrey Conn, Katrina A. Bollinger, Rory Capstick, Paul Spearing, Sean R. Bollinger
  • Positive allosteric modulators of the muscarinic acetylcholine receptor M1
    Patent number: 10899759
    Abstract: Described are positive allosteric modulators of muscarinic acetylcholine receptor M1(mAChR M1), pharmaceutical compositions including the compounds, and methods of using the compounds and compositions for treating neurological disorders, psychiatric disorders, or a combination thereof.
    Type: Grant
    Filed: August 16, 2017
    Date of Patent: January 26, 2021
    Assignee: Vanderbilt University
    Inventors: Craig W. Lindsley, P. Jeffrey Conn, Katrina A. Bollinger, Darren W. Engers, Anna L. Blobaum, Julie L. Engers, Jerri M. Rook
  • POSITIVE ALLOSTERIC MODULATORS OF THE MUSCARINIC ACETYLCHOLINE RECEPTOR M1
    Publication number: 20200024275
    Abstract: Described are positive allosteric modulators of muscarinic acetylcholine receptor M1(mAChR M1), pharmaceutical compositions including the compounds, and methods of using the compounds and compositions for treating neurological disorders, psychiatric disorders, or a combination thereof.
    Type: Application
    Filed: August 16, 2017
    Publication date: January 23, 2020
    Inventors: Craig W. Lindsley, P. Jeffrey Conn, Katrina A. Bollinger, Darren W. Engers, Anna L. Blobaum, Julie L. Engers, Jerri M. Rook
  • 4,5-substituted picolinamide and picolinonitrile metabotropic glutamate receptor 2 negative allosteric modulators
    Patent number: 10538491
    Abstract: 4,5-Substituted Picolinamide and picolinonitrile compounds of formula (I), where R4 is CONH2 or CN and R1 is an optionally substituted aryl or heteroaryl, are negative allosteric modulators of the metabotropic glutamate receptor 2 (mGlu2). The compounds and pharmaceutical compositions including the compounds may be useful for treating depression, anxiety, obsessive-compulsive disorder, cognitive disorders, Alzheimer's disease, or autism spectrum disorders in a subject.
    Type: Grant
    Filed: March 16, 2016
    Date of Patent: January 21, 2020
    Assignee: Vanderbilt University
    Inventors: P. Jeffrey Conn, Craig W. Lindsley, Kyle A. Emmitte, Andrew S. Felts, Katrina A. Bollinger
  • POSITIVE ALLOSTERIC MODULATORS OF THE MUSCARINIC ACETYLCHOLINE RECEPTOR M4
    Publication number: 20190330225
    Abstract: Disclosed herein are pyrido[3?,2?:4,5]thieno[3,2-d]pyrimidine and pyrimido[4?,5?:4,5]thieno[2,3-c]pyridazine compounds, which may be useful as positive allostenc modulators of the muscarinic acetylcholine receptor M4 (mAChR M4). Also disclosed herein are methods of making the compounds, pharmaceutical compositions comprising the compounds, and methods of treating neurological and psychiatric disorders associated with muscarinic acetylcholine receptor dysfunction using the compounds and compositions.
    Type: Application
    Filed: November 7, 2017
    Publication date: October 31, 2019
    Inventors: Craig W. Lindsley, Darren W. Engers, P. Jeffrey Conn, Katrina A. Bollinger, Rory Capstick, Paul Spearing, Sean R. Bollinger
  • Negative allosteric modulators of metabotropic glutamate receptor 3
    Patent number: 10399948
    Abstract: Described are negative allosteric modulators of metabotropic glutamate receptor 3 (mGlu3), pharmaceutical compositions including the compounds, and methods of using the compounds and compositions for treating depression, cognitive disorders, schizophrenia, Alzheimer's disease, or cancer in a subject.
    Type: Grant
    Filed: February 10, 2016
    Date of Patent: September 3, 2019
    Assignee: Vanderbilt University
    Inventors: P. Jeffrey Conn, Craig W. Lindsley, Kyle A. Emmitte, Julie L. Engers, Katrina A. Bollinger, Megan M. Breiner
  • NEGATIVE ALLOSTERIC MODULATORS OF METABOTROPIC GLUTAMATE RECEPTOR 2
    Publication number: 20180072674
    Abstract: Described are negative allosteric modulators of metabotropic glutamate receptor 2 (mGlu2), pharmaceutical compositions including the compounds, and methods of using the compounds and compositions for treating depression, anxiety, obsessive-compulsive disorder, cognitive disorders, Alzheimer's disease, or autism spectrum disorders in a subject.
    Type: Application
    Filed: March 16, 2016
    Publication date: March 15, 2018
    Applicant: Vanderbilt University
    Inventors: P. Jeffrey Conn, Craig W. Lindsley, Kyle A. Emmitte, Andrew S. Felts, Katrina A. Bollinger
  • NEGATIVE ALLOSTERIC MODULATORS OF METABOTROPIC GLUTAMATE RECEPTOR 3
    Publication number: 20180022712
    Abstract: Described are negative allosteric modulators of metabotropic glutamate receptor 3 (mGlu3), pharmaceutical compositions including the compounds, and methods of using the compounds and compositions for treating depression, cognitive disorders, schizophrenia, Alzheimer's disease, or cancer in a subject.
    Type: Application
    Filed: February 10, 2016
    Publication date: January 25, 2018
    Inventors: P. Jeffrey Conn, Craig W. Lindsley, Kyle A. Emmitte, Julie L. Engers, Katrina A. Bollinger, Megan M. Breiner
  • SUBSTITUTED 4-ALKOXYPICOLINAMIDE ANALOGS AS MGLUR5 NEGATIVE ALLOSTERIC MODULATORS AND METHODS OF MAKING AND USING THE SAME
    Publication number: 20170247366
    Abstract: Disclosed are negative allosteric modulators of the metabotropic glutamate receptor subtype 5 (mGluR5); synthetic methods for making the compounds; pharmaceutical compositions comprising the compounds; and methods of treating neurological and psychiatric disorders associated with glutamate dysfunction using the compounds and compositions. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.
    Type: Application
    Filed: June 25, 2015
    Publication date: August 31, 2017
    Inventors: Kyle A. EMMITTE, Craig W. LINDSLEY, P. Jeffrey CONN, Andrew S. FELTS, Katrina A. Bollinger
  • NEGATIVE ALLOSTERIC MODULATORS OF METABOTROPIC GLUTAMATE RECEPTOR 2
    Publication number: 20160214940
    Abstract: Described are negative allosteric modulators of metabotropic glutamate receptor 2 (mGlu2), pharmaceutical compositions including the compounds, and methods of using the compounds and compositions for treating depression, anxiety, obsessive-compulsive disorder, cognitive disorders, Alzheimer's disease, or autism spectrum disorders in a subject.
    Type: Application
    Filed: January 26, 2016
    Publication date: July 28, 2016
    Inventors: P. Jeffrey Conn, Craig W. Lindsley, Kyle A. Emmitte, Andrew S. Felts, Katrina A. Bollinger
  • Negative allosteric modulators of metabotropic glutamate receptor 2
    Patent number: 9382208
    Abstract: Described are negative allosteric modulators of metabotropic glutamate receptor 2 (mGlu2), pharmaceutical compositions including the compounds, and methods of using the compounds and compositions for treating depression, anxiety, obsessive-compulsive disorder, cognitive disorders, Alzheimer's disease, or autism spectrum disorders in a subject.
    Type: Grant
    Filed: January 26, 2016
    Date of Patent: July 5, 2016
    Assignee: Vanderbilt University
    Inventors: P. Jeffrey Conn, Craig W. Lindsley, Kyle A. Emmitte, Andrew S. Felts, Katrina A. Bollinger